Related Experiment Video

Updated: Mar 6, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.3K

Cardio-oncology Related to Heart Failure: Pediatric Considerations for Cardiac Dysfunction

Kirsten Rose-Felker1, William L Border1, Borah J Hong2

  • 1Department of Pediatrics, Sibley Heart Center Cardiology, 201 Dowman Drive, Atlanta, GA 30322, USA; Division of Pediatric Cardiology, Department of Pediatrics, Emory University School of Medicine, 1405 Clifton Road Northeast, Atlanta, GA 30322, USA.

Heart Failure Clinics
|March 11, 2017
PubMed

Insights

Pediatric cancer survivors face significant risks of cardiovascular disease, a leading cause of death. Early detection of cardiac issues is improving, but better screening and cardioprotective strategies are crucial for improved outcomes.

Area of Science:

  • Pediatric Oncology
  • Cardiology
  • Cancer Survivorship

Background:

  • Pediatric cancer treatments have improved survival rates.
  • Survivors have a higher risk of cardiovascular disease (CVD), a leading cause of death.
  • Current cardiac dysfunction detection methods improve early identification but not outcomes.

Purpose of the Study:

  • To highlight the ongoing challenges in managing CVD in pediatric cancer survivors.
  • To emphasize the need for refined screening and precise risk identification.
  • To advocate for evidence-based cardioprotective strategies for primary and secondary prevention.

Main Methods:

  • Review of current literature on pediatric cancer survivorship and cardiovascular complications.
  • Analysis of advancements in cardiovascular imaging and surveillance techniques.
  • Discussion of existing and needed cardioprotective interventions.

Main Results:

  • Despite improved survival, CVD remains a major threat to pediatric cancer survivors.
  • Earlier detection of cardiac dysfunction is possible but does not guarantee better outcomes.
  • Significant gaps exist in precise risk stratification and effective cardioprotective treatments.

Conclusions:

  • Pediatric cancer survivors require specialized, long-term cardiovascular monitoring.
  • Further research is essential to develop targeted screening tools and evidence-based cardioprotection.
  • Improving cardiovascular health is critical for enhancing the quality of life and survival of these patients.

Keywords:
AnthracyclinesCardiac dysfunctionCardiotoxicityChildhood cancer survivors

More Related Videos

Implantation of Total Artificial Heart in Congenital Heart Disease07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

25.3K
Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model04:55

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model

Published on: May 26, 2023

1.4K

Related Concept Videos

Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.1K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.2K
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
613
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
687
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
558
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
488